Cmp
As of the edition of 20 October 2026, Cmp runs 7 drugs, 7 of them marketed; it is on route A at 0 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Total | 7 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Atorvastatin | none listed | 4 |
| Amlodipine | none listed | 16 |
| Sildenafil | Ends 2030 (exclusivity) | 3 |
| Folic acid | none listed | 0 |
| Tadalafil | none listed | 3 |
| Spironolactone | none listed | 3 |
| Clonidine | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 2 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Cmp needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.